EyePoint announces strategic prioritization, 53% workforce reduction and early conclusion of pivotal wet AMD trials

EyePoint announced a strategic prioritization including a 53% workforce reduction and the early conclusion of its pivotal Phase 3 wet AMD trials, without full completion of the second year of each trial.

Detected & updated continuously · Source: Nebula